Best Practice & Research Clinical Rheumatology
Volume 23, Issue 6 , Pages 805-811 , December 2009

Hormonal deprivation therapy-induced osteoporosis in postmenopausal women with breast cancer

  • Mirieme Ghazi
    • ,
  • Christian Roux

      Affiliations

    • Corresponding Author InformationCorresponding author. Paris-Descartes University, Rheumatology Department, Cochin Hospital, Paris, France. Fax: +33 1 44 07 01 07.

References 

  1. Jemal A, Siegel R, Ward E, et al. Cancer statistics. CA Cancer J Clin. 2006;2006(56):106–130
  2. American Cancer Society . Breast cancer facts & figures 2005–2006. Atlanta (GA): American Cancer Society Inc; 2005;
  3. Chen S, Ye J, Kijima I, Kinoshita Y, Zhou D. Positive and negative transcriptional regulation of aromatase expression in human breast cancer tissue. J Steroid Biochem Mol Biol. 2005;95:17–23
  4. Bruggemeier RW, Hackett JC, Diaz-Cruz ES. Aromatase inhibitors in the treatment of breast cancer. Endocr Rev. 2005;26:331–345
  5. Cummings SR, Browner WS, Bauer D, Stone K, Ensrud K, Jamal S, et al. Endogenous hormones and the risk of hip and vertebral fractures among older women. Study of Osteoporotic Fractures Research Group. N Engl J Med. 1998 Sep 10;339(11):733–738
  6. Oz OK, Hirasawa g Lawson J, et al. Bone phenotype of the aromatase deficient mouse. Journal of Steroid Biochemistry & Molecular Biology. 2001;79:49–59
  7. Miyaura C, Toda K, InadaM Ohshiba T, Matsumoto C, Okada T, et al. Sex- and age-related response to aromatase deficiency in bone. Bioch Biophys Res Com. 2001;280:1062–1068
  8. Baum M. ATAC Trialist's Group. Anastrozole alone or in combination with tamoxifen versus tamoxifen alone for adjuvant treatment of postmenopausal women with early breast cancer: first results of the ATAC randomised trial. Lancet. 2002;359:2131–2139
  9. Howell A, Cuzick J, Baum M, Buzdar A, Dowsett M, Forbes JF, et al. Results of the ATAC (Arimidex, Tamoxifen, Alone or in Combination) trial after completion of 5 years' adjuvant treatment for breast cancer. Lancet. 2005;365:60–62
  10. Locker G, Eastell R. The time course of bone fractures observed in the ATAC (‘Arimidex', Tamoxifen, Alone or in Combination) Trial. Proc Am Soc Clin Oncol. 2003;22:25
  11. Eastell R, Hannon RA, Cuzick J, et al. Effect of an aromatase inhibitor on BMD and bone turnover markers: 2-year results of the Anastrozole, Tamoxifen, Alone or in Combination (ATAC) trial (18233230). J Bone Miner Res. 2006;21:1215–1223
  12. Eastell R, Adams JE, Coleman RE, et al. Effect of anastrozole on bone mineral density: 5-year results from the Anastrozole, Tamoxifen, Alone or in Combination trial 18233230. J Clin Oncol. 2008;26:1051–1058
  13. Goss PE, Ingle JN, Martino S, Robert NJ, Muss HB, Piccart MJ, et al. A randomized trial of letrozole in postmenopausal women after five years of tamoxifen therapy for early-stage breast cancer. N Engl J Med. 2003;349:1793–1802
  14. Perez EA, Josse RG, Pritchard KI, Ingle JN, Martino S, Findlay BP, et al. Effect of letrozole versus placebo on bone mineral density in women with primary breast cancer completing 5 or more years of adjuvant tamoxifen: a companion study to NCIC CTG MA.17. J Clin Oncol. 2006;24:3629–3635
  15. Coates AS, Keshaviah A, Thurlimann B, et al. Five Years of Letrozole Compared With Tamoxifen As Initial Adjuvant Therapy for Postmenopausal Women With Endocrine-Responsive Early Breast Cancer: update of Study BIG 1-98. J Clin Oncol. 2007;25:486–492
  16. Rabaglio M, Sun Z, Price KN, et al. Bone fractures among postmenopausal patients with endocrin-responsive early breast cancer with 5 years of letrozole or tamoxifen in the BIG 1-98 trial. Ann Oncol. 2009;Epub ahead
  17. Coombes RC, Hall E, Gibson LJ, et al. A randomized trial of exemestane after two to three years of tamoxifen therapy in postmenopausal women with primary breast cancer. N Engl J Med. 2004;350:1081–1092
  18. Coleman RE, Banks LM, Girgis SI, Kilburn LS, et al. Skeletal effects of exemestane on bone mineral density, bone biomarkers, and fracture incidence in postmenopausal women with early breast cancer participating in the Intergroup Exemestane Study (IES): a randomised controlled study. Lancet Oncol. 2007;8:119–127
  19. Lønning PE, Geisler J, Krag LE, Erikstein B, Bremnes Y, Hagen AI, et al. Effects of exemestane administered for 2 years versus placebo on bone mineral density, bone iomarkers, and plasma lipids in patients with surgically resected early breast cancer. J Clin Oncol. 2005;23:5126–5137
  20. Camacho PM, Dayal AS, Diaz JL, Nabhan FA, Agarwal M, Norton JG, et al. Prevalence of secondary causes of bone loss among breast cancer patients with ostepenia and osteoporosis. J Clin Oncol. 2008 Nov 20;26(33):5380–5385
  21. Brufsky A, Harker WG, Beck JT, et al. Zoledronic acid inhibits adjuvant letrozole-induced bone loss in postmenopausal women with early breast cancer. J Clin Oncol. 2007;25:829–836
  22. Gnant MF, Mlineritsch B, Luschin-EbengreuthG , et al. Zoledronic acid prevents cancer treatment-induced bone loss in premenopausal women receiving adjuvant endocrine therapy for hormone-responsive breast cancer: A report from the Austrian Breast and Colorectal Cancer Study Group. J Clin Oncol. 2007;25:820–828
  23. Eastell R, Van Poznak C, Hannon R, Clack G, et al. The SABRE (Study of Anastrozole with the Bisphosphonate RisedronatE) study: 12-month results. J Bone Miner Res. 2007;22(suppl 1.):S113
  24. Confavreux CB, Fontana A, Jp F, et al. Estrogen-dependent increase in bone turnover and bone loss in postmenopausal women with breast cancer treated with anastrozole. Prevention with bisphosphonates. Bone. 2007;41:346–352
  25. Ellis GK, Bone HG, Chlebowski R, Paul D, et al. Randomized trial of denosumab in patients receiving adjuvant aromatase inhibitors for nonmetastatic breast cancer. J Clin Oncol. 2008;26(30):4875–4882

PII: S1521-6942(09)00096-5

doi: 10.1016/j.berh.2009.09.003

Best Practice & Research Clinical Rheumatology
Volume 23, Issue 6 , Pages 805-811 , December 2009

Article Tools

* Image Usage & Resolution